Abstract
We investigated the significance of prognostic markersβestrogen receptor, progesterone receptor, p53, MIBβ1 and bclβ2 β in adenocarcinoma of the uterine cervix. In 101 patients with primary cervical adenocarcinoma, treated from 1989 to 2000, we evaluated clinical parameters in relation to these prognostic markers. Mean age of patients was 45 years. Seventy eight percent of the patients were in FIGO stage I, 16% stage II, 7% stage III and IV. estrogen receptor, progesterone receptor, p53 and bclβ2 immunoreactivity was scored as 0 (up to 5% positive cells), 1+ (5β25% of cells positive), 2+ (26β50% of cells positive), 3+ (51β75% of cells positive) or 4+ (>76% of cells positive). MIBβ1 was scored in 10 categories: 0β10, 11β20, 21β30, 31β40, 41β50, 51β60, 61β70, 71β80, 81β90, 91β100. The overall survival rate was 67%. Survival was not influenced by estrogen receptor, progesterone receptor, MIBβ1, or bclβ2 strongly positive staining. Only p53 showed significant influence on survival, even when adjusted for stage or tumor grade. In conclusion, it does not seems useful to determine estrogen receptor, progesterone receptor, MIBβ1 or bclβ2 in cervical adenocarcinomas as an indication of prognosis: survival is not influenced by presence or absence. However, if p53 staining is strongly positive survival is significantly worse than in tumors scored as negative or weak positive. Β© 2007 WileyβLiss, Inc.